3-methyl-5-[3-(2-morpholin-4-yl-ethylamino)-propyl]-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester | 1082989-99-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 3-methyl-5-[3-(2-morpholin-4-yl-ethylamino)-propyl]-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester
• 英文别名: 2-O-tert-butyl 4-O-ethyl 3-methyl-5-[3-(2-morpholin-4-ylethylamino)propyl]-1H-pyrrole-2,4-dicarboxylate
• CAS: 1082989-99-8
• 化学式: C₂₂H₃₇N₃O₅
• 分子量: 423.553
• InChiKey: IVRUVDGTALBEJC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  30
• 可旋转键数：
  13
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  92.9
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  3-methyl-5-[3-(2-morpholin-4-yl-ethylamino)-propyl]-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester 在 三甲基铝 、 原甲酸三乙酯 、 三氟乙酸 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 1.67h， 生成 (Z)-2-(5-fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-3-methyl-5-(2-morpholin-4-yl-ethyl)-5,6,7,8-tetrahydro-1H-pyrrolo[3,2-c]azepin-4-one
  参考文献：
  名称：

  Novel Potent Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitors: Synthesis, Structure−Activity Relationships, and Antitumor Activities of 2-Indolinone Derivatives

  摘要：

  The inhibition of receptor tyrosine kinases (RTKs) has become a successful approach in the development of anticancer agents. Many potent small-molecule kinase inhibitors have been discovered. We report herein a series of pyrrolo-fused-heterocycle-2-indolinone analogues as inhibitors of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR). and c-Kit. Among them, some pyrrolo-fused six- and seven-membered-heterocycle derivatives such as 9, 15, 23, and 25 are potent inhibitors of VEGFR, PDGFR, and c-Kit both enzymatically ( < 50 nM) and cellularly, ( < 50 nM). Furthermore, compounds 9 and 25 possess favorable pharmacokinetic profiles and demonstrate good efficacies against human HT-29 cell colon tumor xenografts in nude mice. Further evaluations are in progress.

  DOI：

  10.1021/jm101036c
• 作为产物：
  描述：

  3,5-二甲基-1-氢-吡咯-2-羧酸叔丁酯-4-羧酸乙酯 在 ammonium cerium (IV) nitrate 、 palladium 10% on activated carbon 、 水 、 氢气 、 溶剂黄146 、 三乙胺 、 diborane(6) 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 3-methyl-5-[3-(2-morpholin-4-yl-ethylamino)-propyl]-1H-pyrrole-2,4-dicarboxylic acid 2-tert-butyl ester 4-ethyl ester
  参考文献：
  名称：

  Novel Potent Orally Active Multitargeted Receptor Tyrosine Kinase Inhibitors: Synthesis, Structure−Activity Relationships, and Antitumor Activities of 2-Indolinone Derivatives

  摘要：

  The inhibition of receptor tyrosine kinases (RTKs) has become a successful approach in the development of anticancer agents. Many potent small-molecule kinase inhibitors have been discovered. We report herein a series of pyrrolo-fused-heterocycle-2-indolinone analogues as inhibitors of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR). and c-Kit. Among them, some pyrrolo-fused six- and seven-membered-heterocycle derivatives such as 9, 15, 23, and 25 are potent inhibitors of VEGFR, PDGFR, and c-Kit both enzymatically ( < 50 nM) and cellularly, ( < 50 nM). Furthermore, compounds 9 and 25 possess favorable pharmacokinetic profiles and demonstrate good efficacies against human HT-29 cell colon tumor xenografts in nude mice. Further evaluations are in progress.

  DOI：

  10.1021/jm101036c

文献信息

• PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIES,THE PREPARATION AND THE PHARMCETICAL USE THEEOF
  申请人：ChoTang Peng Cho

  公开号：US20100075952A1

  公开（公告）日：2010-03-25

  The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

  该发明提供了由式(I)表示的新的吡咯基氮杂环衍生物或其盐，其制备方法，含有这种衍生物的药物组合物以及将这种衍生物用作治疗剂，特别是蛋白激酶抑制剂的用途，其中式(I)中的每个取代基与描述中定义的相同。
• Pyrrolo-nitrogenous heterocyclic derivatives, the preparation and the pharmaceutical use thereof
  申请人：Shanghai Hengrui Pharmaceutical Co., Ltd.

  公开号：US08329682B2

  公开（公告）日：2012-12-11

  The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

  该发明提供了由式（I）表示的新的吡咯-含氮杂环衍生物或其盐，其制备方法，含有这种衍生物的药物组合物以及将这种衍生物用作治疗剂，特别是作为蛋白激酶抑制剂的用途，其中式（I）中的每个取代基与描述中定义的相同。
• Methods of Inhibiting the Catalytic Activity of a Protein Kinase and of Treating a Protein Kinase Related Disorder
  申请人：JIANGSU HANSOH PHARMACEUTICAL CO., LTD.

  公开号：US20130303518A1

  公开（公告）日：2013-11-14

  The invention provides a method of inhibiting the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, and also provides a method of treating a protein kinase related disorder comprising a step of administering to a patient in need thereof a therapeutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, wherein each substituent in formula (I) is same as defined in the description.

  本发明提供了一种抑制蛋白激酶催化活性的方法，包括将该蛋白激酶与式(I)的化合物或其药学上可接受的盐或含有该化合物的制剂接触。本发明还提供了一种治疗与蛋白激酶相关的疾病的方法，包括向需要治疗的患者施用式(I)的化合物或其药学上可接受的盐或含有该化合物的制剂的治疗有效量。式(I)中的每个取代基与说明书中定义的相同。
• PYRROLO-NITROGENOUS HETEROCYCLIC DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF
  申请人：Shanghai Hengrui Pharmaceutical Co. Ltd.

  公开号：EP2157093A1

  公开（公告）日：2010-02-24

  The invention provides new pyrrolo-nitrogenous heterocyclic derivatives represented by formula (I) or their salts, the preparation thereof, pharmaceutical compositions containing such derivatives and the use of such derivatives as therapeutic agents, especially as protein kinase inhibitors, wherein each substituent in formula (I) is same as defined in the description.

  本发明提供了式 (I) 所代表的新的吡咯氮杂环衍生物或其盐类、其制备方法、含有此类衍生物的药物组合物以及此类衍生物作为治疗剂，特别是作为蛋白激酶抑制剂的用途，其中式 (I) 中的每个取代基与描述中所定义的相同。
• EP2157093
  申请人：——

  公开号：——

  公开（公告）日：——